Quercetin (Sophoretin; NSC 9221; Kvercetin)

别名: NSC 9221; NCI-C60106; NSC 9219; Meletin; Quercetin; Kvercetin; Quercetine; Quercetol; Sophoretin; Meletin; Quercetine; Quertine; Quertine; Sophoretin; Xanthaurine 槲皮素; 2-(3,4-二羟苯基)-3,5,7-三羟基-4H-1-苯并吡喃-4-酮; 3,3’,4’,5,7-五羟基黄酮; 槲皮黄素; 栎精; 桷皮素; 皮黄素;3,5,7,3',4'-五羥黃酮;栎皮酮; 槲皮黄酮;槲皮素,BR;槲皮素 植物提取物,标准品,对照品;槲皮素,穿琥宁;槲皮素-[13C3];槲皮素-[13C3]同位素内标;槲皮素标准品;槲皮素对照品; 榭皮素;异槲皮素;3,3'',4'',5,7-五羟基黄酮;3,3',4',5,7-五羟基黄酮,2-(3,4-二羟苯基)-3,5,7-三羟基-4H-1-苯并吡喃-4-酮,槲皮黄素,栎精;3,3‘,4‘,5,7-五羟基黄酮;槲皮素(栎精,槲皮黄素);槲皮素(无水);栎精.槲皮黄素; 3,3',4',5,7-五羟基黄酮;栎皮粉;槐花提取物;槲皮素无水物; 无水槲皮素; 槲皮素,栎精,槲皮黄素
目录号: V0147 纯度: ≥98%
槲皮素(Sophoretin;NSC-9221;Kvercetin)是一种从各种蔬菜、水果和葡萄酒中分离出来的天然黄酮类化合物。
Quercetin (Sophoretin; NSC 9221; Kvercetin) CAS号: 117-39-5
产品类别: PI3K
产品仅用于科学研究,不针对患者销售
规格 价格 库存 数量
10 mM * 1 mL in DMSO
500mg
1g
5g
10g
25g
50g
Other Sizes

Other Forms of Quercetin (Sophoretin; NSC 9221; Kvercetin):

  • Quercetin-d3 hydrate
  • Quercetin-d3 (槲皮素 d3)
  • Taxifolin-d3-Dihydroquercetin-d3;-Taxifolin-d3)
  • 二水槲皮素
  • Quercetin hydrate
  • Quercetin 3,3'-dimethyl ether
  • Quercetin 3-O-(6''-O-galloyl)-β-D-glucoside (Tellimoside)
  • Quercetin-3,4-di-O-glucoside
  • Quercetin 3-O-sophoroside-7-O-rhamnoside
  • Quercetin-d5 (槲皮素 d5)
  • Quercetin-13C3 (quercetin 13C3)
  • (±)-Taxifolin-13C3 ((±)-Dihydroquercetin-13C3)
点击了解更多
InvivoChem产品被CNS等顶刊论文引用
纯度/质量控制文件

纯度: ≥98%

产品描述
槲皮素(Sophoretin;NSC-9221;Kvercetin)是从各种蔬菜、水果和酒中分离出来的天然黄酮类化合物。据报道,槲皮素具有多种生物活性,包括对癌细胞的抗炎、抗氧化和促凋亡功能。作为一种 PI3K 抑制剂,IC50 范围为 2.4–5.4 μM,并作为重组 SIRT1 的刺激剂,它以多种方式抑制肿瘤生长。由于槲皮素对糖尿病患者有利,因此它是许多膳食补充剂的成分。
生物活性&实验参考方法
靶点
PI3Kδ (IC50 = 2.4 μM); PI3Kγ (IC50 = 3 μM); PI3Kβ (IC50 = 5.4 μM); Autophagy; Mitophagy
体外研究 (In Vitro)
槲皮素是一种黄酮醇和植物来源的类黄酮,是一种植物化学物质或植物化学物质,存在于水果、蔬菜、叶子和谷物中。补充剂、饮料和食品都可能含有它作为成分。人们正在研究它的广泛潜在健康益处,包括多项研究表明的抗炎和抗氧化特性。槲皮素 (Sophoretin) 抑制 PI3K,IC50 范围为 2.4 至 5.4 M。它严重抑制 PI3K 和 Src 激酶,仅轻微影响 Akt1/2、PKC、p38 和 ERK1/2,对 PI3K 和 Src 激酶几乎没有任何影响。 [1]槲皮素可阻断 TNF 诱导的 LDH% 释放、EC 依赖性中性粒细胞对牛肺动脉内皮细胞 (BPAEC) 的粘附以及 BPAEC DNA 合成和增殖。 [2]
体内研究 (In Vivo)
槲皮素 (75 mg/kg) 和 2-甲氧基雌二醇的组合可增强对人前列腺癌 LNCaP 和 PC-3 细胞异种移植肿瘤生长的抑制。 [3]
酶活实验
槲皮素是一种植物性化学物质或植物化学物质,被称为黄酮醇和植物源性黄酮类化合物,存在于水果、蔬菜、叶子和谷物中。它也可以用作补充剂、饮料或食品的成分。在多项研究中,它可能具有抗炎和抗氧化特性,并且正在研究它是否具有广泛的潜在健康益处。 Quercetin (Sophoretin) 是一种 PI3K 抑制剂,IC50 为 2.4 – 5.4 μM。它强烈消除 PI3K 和 Src 激酶,轻度抑制 Akt1/2,并轻微影响 PKC、p38 和 ERK1/2。槲皮素抑制 TNF 诱导的 LDH% 释放、EC 依赖性中性粒细胞与牛肺动脉内皮细胞 (BPAEC) 的粘附以及 BPAEC DNA 合成和增殖。
细胞实验
细胞用不同浓度的药物处理24小时。
肿瘤组织与含有蛋白酶抑制剂混合物的RIPA-Lysis缓冲液混合。将裂解物离心并收集上清液。使用BCA蛋白检测试剂盒定量后,通过6%-12%SDS-PAGE分离80μg蛋白,并将其转移到聚偏二氟乙烯(PVDF)膜上,然后用5%脱脂乳封闭,并与一抗一起孵育:Bcl-2、Bax(1:1000)、Caspase-3(1:100)、AKT和pAKT(1:1000,VEGF(1:500)在4°C下过夜,GAPDH(1:10000,σ)在室温下孵育1小时,然后用辣根过氧化物酶偶联的二抗(1:2000)在室温上孵育另外1小时。通过增强化学发光试剂盒检测抗原-抗体复合物条带。GAPDH用作负荷对照。[3]
动物实验
On the right back of mice, 2×108 LNCaP cells and 5 105 PC-3 cells suspended in 100 liters of matrigel and PBS are inoculated subcutaneously. Mice are randomly assigned to four groups (n=8 in each group) and treated intraperitoneally when xenograft tumors have grown to a volume of about 100 mm3.
Before the formal in vivo experiment, we evaluated the toxicity of two combined drugs and vehicle that would be administrated simultaneously using two groups of male BALB/c nude mice (n = 5 each). Solvent for quercetin was 25% hydroxypropyl-β-cyclodextrin (HPβCD, w/v in ddH2O) and for 2-Methoxyestradiol was 25% HPβCD containing 0.5% carboxymethyl cellulose (CMC, w/v in ddH2O). Drug group were given the two drugs, namely dissolved quercetin and 2-ME, and vehicle control group were given two drug-free vehicles, namely 25% HPβCD containing or not containing 0.5% CMC. After operation, toxic reaction was observed in the mice of both groups represented as poor mental state, lightly twisting the body, convulsion and occasional moderate haematuria that were in consistent with the description of Ehteda A and may be attributed to high concentration of HPβCD. For this reason, in the subsequent experiment, combination of quercetin and 2-ME was carried out in this way: quercetin was given on day 1, followed by 2-ME given on day 2.[3]

Mice were inoculated subcutaneously with 5×105 PC-3 cells suspended in 100μL PBS and 2×108 LNCaP cells suspended in 100μL of matrigel and PBS mixture (1:1) on the right back. When xenograft tumors reached a volume of approximately 100mm3, mice were randomly assigned to four groups (n = 8 each group) and treated intraperitoneally. Therapeutic schedule based on our in vitro results, preliminary experiments and many other researchers' studies was as follows: (1) Vehicle control group: vehicle of quercetin on day 1, vehicle of 2-ME on day 2, (2) Quercetin treated group: quercetin 75mg/kg on day 1, vehicle of 2-ME on day 2, (3) 2-ME treated group: vehicle of quercetin on day 1, 2-ME 150mg/kg on day 2, (4) Combination treatment group: quercetin 75mg/kg on day 1, 2-ME 150mg/kg on day 2. Two days was a treatment cycle and the whole treatment process lasted for 4 weeks. Tumor sizes were monitored every 2 days using caliper and tumor volume were calculated according to the formula: L×S2×0.5, in which L represents the longest diameter and S represents the shortest diameter of tumor. Mice were weighed as well. At the end of treatment procedure, on day 29, mice were anesthetized with chloral hydrate and sacrificed by cervical dislocation. Xenograft tumors were taken out quickly and weighed. One part of it was put into liquid nitrogen immediately for future biomarker analysis and the other part was fixed in 10% neutral buffered formalin for immunohistochemical analysis. Serum biochemical parameters such as ALT, AST, creatinine and urea nitrogen that reflected drug toxicity were also detected.[3]
药代性质 (ADME/PK)
Absorption, Distribution and Excretion
After oral administration of a single dose of 4 g quercetin to four male and two female volunteers, neither quercetin nor its conjugates was detected in the blood or urine during the first 24 hr; 53% of the dose was recovered in the feces within 72 hr. After a single intravenous injection of 100 mg quercetin to six volunteers, the blood plasma levels declined biphasically, with half-lives of 8.8 min and 2.4 hr; protein binding exceeded 98%. In the urine, 0.65% of the intravenous dose was excreted as unchanged quercetin and 7.4% as a conjugate within 9 hr; no further excretion occurred up to 24 hr ...
When 14C-quercetin was administered orally to ACI rats, about 20% of the administered dose was absorbed from the digestive tract, more than 30% was decomposed to yield 14-CO2 & about 30% was excreted unchanged in feces..
One male and one female volunteer were given a diet containing quercetin glucosides (64.2 mg expressed as the aglycone). The mean peak plasma concentration of quercetin was 196 ng/mL which was reached 2.9 hr after ingestion. The time-course of the plasma concentration of quercetin was biphasic, with half-lives of 3.8 hr for the distribution phase and 16.8 hr for the elimination phase. Quercetin was still present in plasma 48 hr after ingestion ... /Quercetin glucosides/
Autoradiographic analysis of a fasted rat 3 hr after administration of a single oral dose of 2.3 mg/kg (4-(14)C)quercetin showed that although most of the radiolabel remained in the digestive tract it also occurred in blood, liver, kidney, lung and ribs. After oral administration of 630 mg/kg of the labelled compound to rats, 34% of the radiolabel excreted within 24 hr ... was expired carbon dioxide, 12% in bile and 9% in urine; within 48 hr, 45% was recovered in the feces. Approximately 60% of the radiolabel in the feces was identified as unmetabolized quercetin ...
For more Absorption, Distribution and Excretion (Complete) data for QUERCETIN (9 total), please visit the HSDB record page.
Metabolism / Metabolites
The glycosides are hydrolyzed in the body to corresponding aglycones, which are then further metabolized by scission of the heterocyclic ring to give 3,4-dihydroxy-phenyl-substituted acids ... The site of ring scission depends on structure ... with flavonols (quercetin) scission occurs at the 1,2 & 3,4 bonds to yield homoprotocatechuic acid ... These acids are further metabolized by beta-oxidation of acyl side-chain, o-methylation & demethylation, & aromatic dehydroxylation.
o-Beta-hydroxyethylated derivatives of quercetin were isolated from urine samples & separated by HPLC. The 5,7,3',4'-tetra compd was separated from 3,7,3',4'-tetra derivative. The 7,3',4'-tri & 7'-mono compounds gave 1 common peak, separated from the peak for the 7,4'-di compd.
After oral admin to ACI rats, the absorbed (14)C-quercetin was rapidly excreted into the bile & urine within 48 hr as the glucuronide & sulfate conjugates of (14)C-quercetin, 3'-o-monomethyl quercetin & 4'-o-monomethyl quercetin. Efficient metabolism and elimination of quercetin may be one reason for the lack of carcinogenicity in rats.
The metabolites of quercetin flavonols identified in urine samples collected from two male volunteers who consumed their habitual diets for three days were 3,4-dihydroxyphenylacetic acid, meta-hydroxyphenylacetic acid, and 4-hydroxy-3-methoxyphenylacetic acid ...
For more Metabolism/Metabolites (Complete) data for QUERCETIN (10 total), please visit the HSDB record page.
Quercetin has known human metabolites that include Mikwelianin and Dihydroquercetin.
Quercetin is a known human metabolite of Quercitrin and tamarixetin.
Biological Half-Life
One male and one female volunteer were given a diet containing quercetin glucosides (64.2 mg expressed as the aglycone) ... Half-lives /were/ 3.8 hr for the distribution phase and 16.8 hr for the elimination phase ... /Quercetin glucosides/
...The elimination half-life of quercetin is approx 25 hr.
毒性/毒理 (Toxicokinetics/TK)
Toxicity Summary
Quercetin is a specific quinone reductase 2 (QR2) inhibitor, an enzyme (along with the human QR1 homolog) which catalyzes metabolism of toxic quinolines. Inhibition of QR2 in plasmodium may potentially cause lethal oxidative stress. The inhibition of antioxidant activity in plasmodium may contribute to killing the malaria causing parasites.
Hepatotoxicity
Quercetin supplements have not been linked serum aminotransferase elevations during therapy, although there have been few focused studies of its hepatic safety. Furthermore, there have been no published reports of clinically apparent liver injury attributable to quercetin. Indeed, many in vitro and in vivo studies have shown that quercetin protects against hepatic injury caused by drugs and toxins including acetaminophen and cancer chemotherapeutic agents. These hepatoprotective effects have not been demonstrated in prospective clinical trials in humans.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
Other Names: Often a component in Bioflavonoid Extracts
Drug Class: Herbal and Dietary Supplements
Interactions
In human myelogenous leukemia cells, quercetin was reported to arrest growth of the cell by an incr in the uptake of vincristine, a chemotherapeutic agent.
Quercetin binds, in vitro, to the DNA gyrase site in bacteria. Therefore, theoretically, it can serve as a competitive inhibitor to the quinolone antibiotics which also bind to this site ... Because of the theoretical risk of genotoxicity in normal tissues in those using cisplatin along with quercetin, those using cisplatin should avoid quercetin supplements ... Bromelain and papain are reported to incr absorption of quercetin.
Quercetin has a pro-oxidant effect and will incr the iron-dependent DNA damage induced by bleomycin. Quercetin may reduce iron to the ferrous state, which allows bleomycin to complex more readily with oxygen and produce more efficient DNA damage. A biphasic pro-oxidant effect with bleomycin has been demonstrated. At low concn incr DNA damage was noted, and at higher doses less DNA damage was noted.
Concomitant use may reduce cyclosporine /or floroquinolones/ effectiveness.
For more Interactions (Complete) data for QUERCETIN (18 total), please visit the HSDB record page.
Non-Human Toxicity Values
LD50 Rat oral 161 mg/kg
LD50 Mouse iv 18 mg/kg
LD50 Mouse oral 160 mg/kg
LD50 Mouse sc 100 mg/kg
参考文献

[1]. Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. Fitoterapia. 2010 Mar;81(2):75-80.

[2]. Inhibitory effects of protein kinase C inhibitors on tumor necrosis factor induced bovine pulmonary artery endothelial cell injuries. Yao Xue Xue Bao. 1996;31(3):176-81.

[3]. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth. PLoS One. 2015 May 26;10(5):e0128277.

[4]. Quercetin alleviates kidney fibrosis by reducing renal tubular epithelial cell senescence through the SIRT1/PINK1/mitophagy axis. Life Sci. 2020 Jul 20;118116.

其他信息
Therapeutic Uses
Quercetin has been used in medicine to decrease capillary fragility.
/EXPL THER/ ... In a randomized, double-blind, placebo-controlled trial ... /among patients with category III chronic prostatitis syndromes (nonbacterial chronic prostatitis and prostatodynia)/ ... Significant improvement was achieved in the treated group, as measured by the NIH chronic prostatitis score. Some 67% of the treated subjects had at least 25% improvement in symptoms, compared with 20% of the placebo group achieving this same level of improvement. In a follow up, unblind, open-label study ... quercetin was combined with bromelain and papain, which may enhance its absorption. In this study, 82% achieved a minimum 25% improvement score.
/EXPL THER/ Lymphocyte protein kinase phosphorylation was inhibited by quercetin in 9 of 11 cancer patients in a phase I clinical trial. Fifty-one patients with microscopically confirmed cancer not amenable to standard therapies and with a life expectancy of at least 12 wk participated in this trial ... The patients were treated at 3-wk intervals at the beginning of the study. Quercetin was admin iv as quercetin dihydrate ... The max allowed dose was reached when 2 of 3 patients on each dose schedule reached grade 3 or 4 general toxicity, or grad 2 renal toxicity, cardiac toxicity, or neurotoxicity. Phosphorylation was inhibited at 1 hr and persisted for 16 hr. In one patient with ovarian cancer refractory to cisplatin, cancer antigen-125 (CA 125) fell from 295 to 55 units/mL after treatment with 2 courses of quercetin ... A hepatoma patient had serum alpha-fetoprotein fall.
/EXPL THER/ ... Quercetin was reported to inhibit tumor necrosis factor-alpha (TNF-alpha) overproduction and attenuate pathophysiological conditions during acute and chronic inflammation ... In asthma, the activation of mast cells and basophils by allergen releases chemical mediators and synthesizeds cytokines leading to inflammatory conditions ... Quercetin was reported to inhibit cytokine expression and synthesis by human basophils ... A metabolite of quercetin, 3-O-methylquercetin (3-MQ), was reported to provide beneficial effects on asthma by inhibiting cAMP- and cGMP-phosphodiesterase (PDE). ...
Drug Warnings
Although quercetin seems to have potential as an anticancer agent, future studies are needed, because most studies are based on in vitro experiments using high concn of quercetin unachievable by dietary ingestion, and because its beneficial effects on cancer are still inconclusive in animal and/or human studies.
... Quercetin has been shown to protect low density lipoprotein (LDL) from oxidation and prevent platelet aggregation. It was also reported to inhibit the proliferation and migration of smooth muscle cells ... Quercetin was reported to significantly lower the plasma lipid, lipoprotein and hepatic cholesterol levels, inhibit the production of oxLDL produced by oxidative stress, and protect an enzyme, which can hydrolyzed specific lipid peroxides in oxidized lipoproteins and in atherosclerotic lesions ... /It/ induced endothelium-dependent vasorelaxation in rat aorta via incr nitric oxide production ... Quercetin and its glycosides were also reported to inhibit the angiotensin-converting enzyme activity, and ANG II-induced JNK activation inducing vascular smooth muscle cell (VSMC) hypertrophy ... However, some effects may not be feasible or negligible in physiological conditions, because concn of quercetin in most studies are too high to be achieved by dietary ingestion ... and beneficial effects of quercetin on cardiovascular diseases are still inconclusive in human studies ...
*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性
化学信息 & 存储运输条件
分子式
C15H10O7
分子量
302.2357
精确质量
302.042
元素分析
C, 59.61; H, 3.34; O, 37.05
CAS号
117-39-5
相关CAS号
Quercetin-d3;263711-79-1;Quercetin dihydrate;6151-25-3;Quercetin hydrate;849061-97-8;Quercetin;117-39-5;Quercetin-d5;263711-78-0;Quercetin-13C3
PubChem CID
5280343
外观&性状
Light yellow to yellow solid powder
密度
1.8±0.1 g/cm3
沸点
642.4±55.0 °C at 760 mmHg
熔点
314-317°C
闪点
248.1±25.0 °C
蒸汽压
0.0±2.0 mmHg at 25°C
折射率
1.823
LogP
2.08
tPSA
131.36
氢键供体(HBD)数目
5
氢键受体(HBA)数目
7
可旋转键数目(RBC)
1
重原子数目
22
分子复杂度/Complexity
488
定义原子立体中心数目
0
SMILES
O1C(=C(C(C2=C(C([H])=C(C([H])=C12)O[H])O[H])=O)O[H])C1C([H])=C([H])C(=C(C=1[H])O[H])O[H]
InChi Key
REFJWTPEDVJJIY-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H
化学名
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
别名
NSC 9221; NCI-C60106; NSC 9219; Meletin; Quercetin; Kvercetin; Quercetine; Quercetol; Sophoretin; Meletin; Quercetine; Quertine; Quertine; Sophoretin; Xanthaurine
HS Tariff Code
2934.99.9001
存储方式

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

运输条件
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
溶解度数据
溶解度 (体外实验)
DMSO: ~61 mg/mL (~201.8 mM)
Water: <1 mg/mL
Ethanol: ~10 mg/mL (~33.1 mM)
溶解度 (体内实验)
配方 1 中的溶解度: ≥ 2.5 mg/mL (8.27 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

配方 2 中的溶解度: ≥ 2.5 mg/mL (8.27 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。
*20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。

View More

配方 3 中的溶解度: 2% DMSO+30% PEG 300+2% Tween 80+ddH2O: 6mg/mL


配方 4 中的溶解度: 25 mg/mL (82.72 mM) in 0.5% CMC-Na/saline water (这些助溶剂从左到右依次添加,逐一添加), 悬浊液; 超声助溶。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

配方 5 中的溶解度: 10 mg/mL (33.09 mM) in 45% PEG300 5% Tween-80 50% Saline (这些助溶剂从左到右依次添加,逐一添加), 悬浊液; 超声助溶。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

配方 6 中的溶解度: 10 mg/mL (33.09 mM) in 50% PG 50% Saline (这些助溶剂从左到右依次添加,逐一添加), 悬浊液; 超声助溶。
*生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。

请根据您的实验动物和给药方式选择适当的溶解配方/方案:
1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL;

3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果,工作液请现配现用!
6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。
制备储备液 1 mg 5 mg 10 mg
1 mM 3.3086 mL 16.5431 mL 33.0863 mL
5 mM 0.6617 mL 3.3086 mL 6.6173 mL
10 mM 0.3309 mL 1.6543 mL 3.3086 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;

3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);

4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。

计算器

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度,具体如下:

  • 计算制备已知体积和浓度的溶液所需的化合物的质量
  • 计算将已知质量的化合物溶解到所需浓度所需的溶液体积
  • 计算特定体积中已知质量的化合物产生的溶液的浓度
使用摩尔浓度计算器计算摩尔浓度的示例如下所示:
假如化合物的分子量为350.26 g/mol,在5mL DMSO中制备10mM储备液所需的化合物的质量是多少?
  • 在分子量(MW)框中输入350.26
  • 在“浓度”框中输入10,然后选择正确的单位(mM)
  • 在“体积”框中输入5,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案17.513 mg出现在“质量”框中。以类似的方式,您可以计算体积和浓度。

稀释计算器可计算如何稀释已知浓度的储备液。例如,可以输入C1、C2和V2来计算V1,具体如下:

制备25毫升25μM溶液需要多少体积的10 mM储备溶液?
使用方程式C1V1=C2V2,其中C1=10mM,C2=25μM,V2=25 ml,V1未知:
  • 在C1框中输入10,然后选择正确的单位(mM)
  • 在C2框中输入25,然后选择正确的单位(μM)
  • 在V2框中输入25,然后选择正确的单位(mL)
  • 单击“计算”按钮
  • 答案62.5μL(0.1 ml)出现在V1框中
g/mol

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成,具体如下:

注:化学分子式大小写敏感:C12H18N3O4  c12h18n3o4
计算化合物摩尔质量(分子量)的说明:
  • 要计算化合物的分子量 (摩尔质量),请输入化学/分子式,然后单击“计算”按钮。
分子质量、分子量、摩尔质量和摩尔量的定义:
  • 分子质量(或分子量)是一种物质的一个分子的质量,用统一的原子质量单位(u)表示。(1u等于碳-12中一个原子质量的1/12)
  • 摩尔质量(摩尔重量)是一摩尔物质的质量,以g/mol表示。
/

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

  • 输入试剂的质量、所需的配液浓度以及正确的单位
  • 单击“计算”按钮
  • 答案显示在体积框中
动物体内实验配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶/难溶于水的化合物),不同的产品和批次配方组成不同,如对配方有疑问,可先联系我们提供正确的体内实验配方。此外,请注意这只是一个配方计算器,而不是特定产品的确切配方。
+
+
+

计算结果:

工作液浓度 mg/mL;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
            (2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息
NCT Number Status Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01720147 Active
Recruiting
Drug: Quercetin
(dietary supplement)
Fanconi Anemia Children's Hospital Medical
Center, Cincinnati
July 2012 Phase 1
NCT04907253 Active
Recruiting
Drug: Quercetin
Drug: Placebo
Coronary Artery Disease Montreal Heart Institute June 4, 2021 Phase 2
NCT04313634 Active
Recruiting
Drug: Fisetin
Drug: Quercetin
Healthy Sundeep Khosla, M.D. June 9, 2020 Phase 2
NCT02226484 Completed Drug: Quercetin GERD
Reflux
University of North Carolina,
Chapel Hill
August 2014 Phase 1
NCT03476330 Recruiting Drug: Quercetin
(dietary supplement)
Fanconi Anemia
Squamous Cell Carcinoma
Children's Hospital Medical
Center, Cincinnati
May 8, 2018 Phase 2
生物数据图片
  • Quercetin

    Quercetin combined with 2-ME enhanced inhibition of PC-3 xenograft tumor growth. Yang F, et al. PLoS One. 2015, 10(5), e0128277.

  • Quercetin


    Quercetin combined with 2-ME decreased pAKT protein expression in PC-3 and LNCaP xenograft tumor tissues.

  • Quercetin

    Quercetin combined with 2-ME decreased VEGF protein and mRNA in PC-3 and LNCaP xenograft tumor tissues.

相关产品
联系我们